Pharma Pioneer

CYP-006TK Clinical Trial for Diabetic Foot Ulcers Completes Patient Recruitment

16 May 2024
2 min read

Cynata Therapeutics, an Australian biotech firm specializing in cell therapies, has successfully completed patient recruitment for its Phase 1 clinical trial of CYP-006TK, a treatment for diabetic foot ulcers (DFU). The trial involves 30 participants with DFU, who have been randomly assigned to either receive CYP-006TK for four weeks followed by standard care, or standard care alone, for the duration of the study. The patients will be monitored for 24 weeks post-treatment, with the final visit scheduled for September 2024. 

CYP-006TK is a novel wound dressing product derived from Cymerus™ iPSCs, which are induced pluripotent stem cells. These cells are cultured to produce mesenchymal stem cells (MSCs), which are then applied to a silicon-based dressing. DFU is a serious complication for diabetics, often leading to chronic wounds that are slow to heal and can result in severe pain, discomfort, and even amputation if not treated effectively. Initial results from the first 16 patients after a 10-week follow-up period have shown promising signs, with the CYP-006TK group experiencing an 87.6% median reduction in wound surface area, significantly higher than the 51.1% reduction observed in the control group. 

Dr. Jolanta Airey, Cynata's Chief Medical Officer, expressed gratitude to all involved and anticipation for the full study results. Cynata Therapeutics is known for its proprietary Cymerus™ platform technology, which utilizes iPSCs and mesenchymoangioblasts (MCA) to produce cell therapy products economically and at a commercial scale. 

The company's lead product, CYP-001, has shown positive safety and efficacy in treating steroid-resistant acute graft-versus-host disease (GvHD). Other ongoing trials for Cymerus products include Phase 2 for GvHD, Phase 3 for osteoarthritis, and DFU, with a renal transplant trial soon to start. The company's technology has also demonstrated potential in preclinical models for a range of diseases, such as critical limb ischemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, ARDS, and cytokine release syndrome. Cynata Therapeutics is listed on the Australian Securities Exchange under the code CYP and encourages investors to adopt a paperless registration process through Automic Group.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Lead Researcher at City of Hope Presents MT APOLLO Clinical Findings at Global Hematologic Malignancies Summit
Pharma Pioneer
3 min read
Lead Researcher at City of Hope Presents MT APOLLO Clinical Findings at Global Hematologic Malignancies Summit
16 May 2024
The trial focused on MT-601, a novel T cell therapy targeting various tumor antigens, and was well-tolerated by participants, leading to sustained objective responses.
Read →
CytomX Commences Phase 1 Clinical Trial with Patient Dosing of EpCAM-Targeted ADC CX-2051 for Advanced Solid Tumors
Pharma Pioneer
2 min read
CytomX Commences Phase 1 Clinical Trial with Patient Dosing of EpCAM-Targeted ADC CX-2051 for Advanced Solid Tumors
16 May 2024
CytomX Therapeutics has initiated a Phase 1 clinical trial for CX-2051, an antibody drug conjugate (ADC) aimed at treating advanced solid tumors.
Read →
ORYZON Receives FDA Clearance for Iadademstat and Immune Checkpoint Inhibitors Trial in 1L Extensive Stage SCLC
Pharma Pioneer
2 min read
ORYZON Receives FDA Clearance for Iadademstat and Immune Checkpoint Inhibitors Trial in 1L Extensive Stage SCLC
16 May 2024
Oryzon Genomics, a biopharmaceutical firm specializing in epigenetic therapies for diseases with significant medical needs, has received approval from the U.S. FDA to begin a Phase I/II clinical trial.
Read →
Poseida Showcases Phase 1 Results at AACR 2024, Highlighting the Efficacy of P-BCMA-ALLO1 Allogeneic CAR-T for Diverse Myeloma Patients
Pharma Pioneer
3 min read
Poseida Showcases Phase 1 Results at AACR 2024, Highlighting the Efficacy of P-BCMA-ALLO1 Allogeneic CAR-T for Diverse Myeloma Patients
16 May 2024
Encouraging initial findings indicate that individuals with relapsed or refractory multiple myeloma, who experienced progression post BCMA-directed treatments, have shown clinical improvements with P-BCMA-ALLO1, demonstrating a good safety profile.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.